Alector‘s patent involves antibodies binding to human MerTK for therapeutic use. The isolated antibody contains specific amino acid sequences. GlobalData’s report on Alector gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Alector, Personalized cancer vaccines was a key innovation area identified from patents. Alector's grant share as of February 2024 was 23%. Grant share is based on the ratio of number of grants to total number of patents.
Antibody for treating an individual with mertk polypeptide
A recently granted patent (Publication Number: US11897968B2) discloses an isolated antibody that binds to human MerTK, featuring specific amino acid sequences in its heavy and light chain variable regions. The antibody is designed to reduce efferocytosis by phagocytic cells, inhibit the binding of ProS and Gas6 to MerTK, decrease Gas6-mediated phosphorylation of AKT, and potentially induce M1-like macrophage polarization. The patent covers various forms of the antibody, including murine, humanized, bispecific, monoclonal, multivalent, conjugated, and chimeric antibodies, with classifications into IgG, IgM, or IgA classes.
Furthermore, the patent encompasses the use of the antibody in pharmaceutical compositions along with a carrier, as well as methods for producing the antibody through isolated nucleic acids, vectors, and host cells. The disclosed sequences in the heavy and light chains of the antibody provide a basis for its production and potential therapeutic applications. The patent highlights the specificity and functionality of the antibody in targeting MerTK and modulating cellular responses, offering a promising avenue for the development of novel treatments targeting MerTK-related pathways in various diseases.
To know more about GlobalData’s detailed insights on Alector, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
